This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oral Cancer Global Clinical Trials Review, H2, 2012





NEW YORK, March 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Oral Cancer Global Clinical Trials Review, H2, 2012

http://www.reportlinker.com/p0761178/Oral-Cancer-Global-Clinical-Trials-Review-H2-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Oral Cancer Global Clinical Trials Review, H2, 2012

Summary

GlobalData's clinical trial report, "Oral Cancer Global Clinical Trials Review, H2, 2012" provides data on the Oral Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or CompaniesTable of ContentsTable of Contents 2List of Tables 4List of Figures 5Introduction 6Oral Cancer 6Report Guidance 6Clinical Trials by Region 7Clinical Trials by Country 8Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10Top Five Countries Contributing to Clinical Trials in Europe 11Top Countries Contributing to Clinical Trials in North America 12Top Countries Contributing to Clinical Trials in Middle East and Africa 13Top Countries Contributing to Clinical Trials in Central and South America 14Clinical Trials by BRIC Nations 15Clinical Trials by G7 Nations 16Clinical Trials in G7 Nations by Trial Status 17Clinical Trials by E7 Nations 18Clinical Trials in E7 Nations by Trial Status 19Clinical Trials by Phase 20In Progress Trials by Phase 21Clinical Trials by Trial Status 22Unaccomplished Trials of Oral Cancer 23Subjects Recruited Over a Period of Time 26Prominent Sponsors 27Top Companies Participating in Oral Cancer Therapeutics Clinical Trials 29Prominent Drug Comparison 30Clinical Trial Profiles 31Clinical Trial Overview of Top Companies 31PeriRx LLC 31Clinical Trial Overview of PeriRx LLC 31Azienda U.S.L. 4 di Prato 32Clinical Trial Overview of Azienda U.S.L. 4 di Prato 32Shenzhen SiBiono GeneTech 33Clinical Trial Overview of Shenzhen SiBiono GeneTech 33RxKinetix, Inc. 34Clinical Trial Overview of RxKinetix, Inc. 34CEL-SCI Corporation 35Clinical Trial Overview of CEL-SCI Corporation 35Pfizer Inc. 36Clinical Trial Overview of Pfizer Inc. 36Clinical Trial Overview of Top Universities / Institutes / Hospitals 37National Taiwan University Hospital 37Clinical Trial Overview of National Taiwan University Hospital 37The University of Texas M. D. Anderson Cancer Center 38Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 38Tata Memorial Hospital 39Clinical Trial Overview of Tata Memorial Hospital 39Stanford University 40Clinical Trial Overview of Stanford University 40Roswell Park Cancer Institute 41Clinical Trial Overview of Roswell Park Cancer Institute 41Fred Hutchinson Cancer Research Center 42Clinical Trial Overview of Fred Hutchinson Cancer Research Center 42Institut Gustave Roussy 43Clinical Trial Overview of Institut Gustave Roussy 43Ohio State University Comprehensive Cancer Center 44Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 44The Ohio State University 45Clinical Trial Overview of The Ohio State University 45UCLA's Jonsson Comprehensive Cancer Center 46Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center 46The University of Chicago 47Clinical Trial Overview of The University of Chicago 47Abramson Cancer Center 48Clinical Trial Overview of Abramson Cancer Center 48Sapporo Medical University 49Clinical Trial Overview of Sapporo Medical University 49Sichuan University 50Clinical Trial Overview of Sichuan University 50Juntendo University School of Medicine 51Clinical Trial Overview of Juntendo University School of Medicine 51Mount Sinai School of Medicine 52Clinical Trial Overview of Mount Sinai School of Medicine 52Virginia Commonwealth University 53Clinical Trial Overview of Virginia Commonwealth University 53Wake Forest University 54Clinical Trial Overview of Wake Forest University 54The University of Mississippi Medical Center 55Clinical Trial Overview of The University of Mississippi Medical Center 55VCU Massey Cancer Center 56Clinical Trial Overview of VCU Massey Cancer Center 56Five Key Clinical Profiles 57Appendix 75Abbreviations 75Definitions 75Research Methodology 76Secondary Research 76About GlobalData 77Contact Us 77Disclaimer 77Source 78

List of Tables

List of Tables

Oral Cancer Therapeutics Market, Global, Clinical Trials by Zone, 2012* 7

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs